OverviewChartNewsTraderScreen

AC IMMUNE SA SF-,02/  CH0329023102  /

Frankfurt
2024-09-20  8:21:03 AM Chg. -0.0100 Volume Bid9:57:56 PM Ask9:58:09 PM High Low
3.2450EUR -0.31% 0
Turnover: 0.0000		 -Bid Size: - -Ask Size: - 3.2450 3.2450
GlobeNewswire 08-28 AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodege...
GlobeNewswire 08-06 AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 07-31 AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy i...
GlobeNewswire 07-25 AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
GlobeNewswire 07-16 AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment...
GlobeNewswire 05-28 AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
GlobeNewswire 05-13 AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 05-13 AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting ...
GlobeNewswire 03-14 AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
GlobeNewswire 02-22 AC Immune Announces Upcoming Presentations at AD/PD™ 2024
GlobeNewswire 01-22 AC Immune to Regain Global Rights to Crenezumab and Semorinemab
GlobeNewswire 01-03 AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Park...
GlobeNewswire 2023-12-15 AC Immune Announces Pricing of Underwritten Offering of Common Shares
GlobeNewswire 2023-12-15 AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b T...
GlobeNewswire 2023-12-01 AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
GlobeNewswire 2023-11-07 AC Immune to Present at the Jefferies 2023 London Healthcare Conference
GlobeNewswire 2023-11-03 AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
GlobeNewswire 2023-11-02 AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of...
GlobeNewswire 2023-10-27 AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589...
GlobeNewswire 2023-10-17 AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
GlobeNewswire 2023-10-05 AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
GlobeNewswire 2023-09-05 AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 20...
GlobeNewswire 2022-03-22 AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
GlobeNewswire 2022-03-21 AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Dis...
GlobeNewswire 2022-03-16 AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurod...